Cell expansion is the large scale artificial production of daughter cells from a single cell, to support medical research. Rising preference for regenerative medicines offering faster results, and emergence of cell-based therapies with high patient compatibility are expected to fuel the cell expansion market during the forecast period (2017–2025). Regenerative medicine helps the body to form new functional tissue to replace defective or lost ones providing treatment for conditions with inadequate therapies. According to the U.S. Department of Health and Services, in 2016, NIH invested around US$ 1.5 billion in stem cell research projects. Increasing government and private sector expenditure on cell-based research therapies is expected to boost growth of the market for cell expansion in the near future. The number of FDA approvals for clinical trials of stem cell-based treatments is rapidly increasing. According to a report published by Pharmaceutical Research and Manufacturers of America, in 2013, around 69 cell therapies with clinical trials were under review with the FDA. The therapeutic classes represented in these trials include skin diseases, cardiovascular diseases, transplantations, eye conditions, cancer and associated conditions, musculoskeletal disorders, genetic disorders, and digestive disorders.
Increasing incidence of chronic medical conditions is expected to boost growth of the cell expansion market over the forecast period
The increasing cases of chronic and rare medical conditions around the world is another key factor driving demand for cell expansion. For instance, according to World Health Organization (WHO), around 15 million people are projected to suffer from cancer by 2020. The rising prevalence of cancer, is in turn, expected to boost growth of the cell expansion market. Cell-based therapy is also a promising approach for treating chronic kidney disease and is presently the focus of preclinical studies. Recent advancements in regenerative medicine and tissue engineering have created cell-based approaches for the treatment of renal failure. Such treatments include biotechnological approach using implantation of bioengineered kidney constructs, transplanting cells, and bio-artificial renal systems. However, lack of high-tech instrumentation and skilled workforce coupled with the high cost of operations are expected to hamper growth of the cell expansion market.
On the basis of product type, the cell expansion market is segmented into:
- Reagents, Serum, and Media
- Cell Expansion Supporting Equipment
- Flow Cytometer
- Cell Counters
- Other Supporting Equipment
- Automated Cell Expansion Systems
On the basis of application, the cell expansion market is segmented into:
- Regenerative Medicine and Stem Cell Research
- Cancer and Cell-based Research
On the basis of cell type, the cell expansion market is segmented into:
- Human Cells
- Stem Cells
- Adult Stem Cells
- Induced Pluripotent Stem Cells
- Embryonic Stem Cells
- Differentiated Cells
- Animal Cells
On the basis of end user, the cell expansion market is segmented into:
- Research Institutes
- Biopharmaceutical and Biotechnology Companies
- Cell Banks
North America is expected to hold a dominant position in the cell expansion market due to increasing demand for regenerative medicines and rising incidence of chronic diseases
Regional segmentation of the cell expansion market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The cell expansion market in North America is driven by the increasing demand for regenerative medicines that are highly compatible with patients and offer rapid results. For instance, the FDA is increasingly approving treatments involving cells derived from bone or blood marrow, due to its well-established efficacy and safety. Furthermore, increasing incidence of chronic diseases and rising R&D investments for the development of cell-based products are other factors expected to support growth of the cell expansion market. For instance in 2018, according to the Centers for Disease Control and Prevention approximately 6 in 10 American citizen have at least one chronic diseases such as cancer, diabetes, and others in the U.S.
According to a study published in NIH report, around 500,000 people benefit from a transplant each year using regenerative medicine in the U.S. Increasing R&D expenditure by several companies for the development of new therapeutic products and availability of untapped growth opportunities are expected to drive the cell expansion market in Asia Pacific. For instance, according to the Indian Brand Equity Foundation reports the Government of India the healthcare expenditure is approximately 1.4 % of total GDP in 2018 as compared to 1.2% in 2014.
Biotechnology merger and acquisition (M&A) activities have also experienced a boost in the region. According to investment bank China Renaissance, in 2016, 37 pharmaceutical and biotech M&A deals worth US$ 6.8 billion were closed in China.
Major industry players use merger and acquisitions as their major growth strategy
Key players operating in the cell expansion market include Becton, Dickinson and Company, Beckman Coulter, Inc., Corning, Inc., GE Healthcare, Lonza, Merck KGaA (Sigma-Aldrich Co. LLC), Miltenyi Biotec, Thermo Fisher Scientific, Inc., Terumo BCT, Inc., and Stemcell Technologies, Inc. In July 2016, GE Healthcare acquired Biosafe SA, a Swiss company that manufactures instruments that recover stem cells and help in various other cell processing procedures related to personalized medicine. This acquisition will help GE Healthcare to grow the cells in the sample for appropriate dose sizes.